Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;507(1):289-293.
doi: 10.1134/S1607672922060114. Epub 2023 Feb 14.

Association of HLA Class I Genotype with Mortality in Patients with Diabetes Mellitus and COVID-19

M Yu Shkurnikov  1   2 , D A Averinskaya  3 , A G Komarov  4 , I A Karbyshev  4 , G I Speshilov  4 , I A Shtinova  4 , D A Doroshenko  5 , V I Vechorko  5 , O M Drapkina  6
Affiliations

Association of HLA Class I Genotype with Mortality in Patients with Diabetes Mellitus and COVID-19

M Yu Shkurnikov et al. Dokl Biochem Biophys. 2022 Dec.

Abstract

Numerous studies showed that diabetes mellitus (DM) increases the risk of death from COVID-19 by five times. It is generally accepted that the high lethality of COVID-19 against the background of DM is due to the main complications of this disease: micro- and macroangiopathies, as well as heart and kidney failure. In addition, it was shown that acute respiratory viral infection increases the production of interferon gamma, increases muscle resistance to insulin, and modulates the activity of effector CD8+ T cells. The ability of CD8+ T cells to recognize SARS-CoV-2-infected cells depends not only on humoral factors but also on individual genetic characteristics, including the individual set of major histocompatibility complex class I (MHC-I) molecules. In this study, the relationship of the MHC-I genotype of patients with DM aged less than 60 years with the outcome of COVID-19 was studied using a sample of 222 patients. It was shown that lethal outcomes of COVID-19 in patients with DM are associated with the low affinity of the interaction of an individual set of MHC-I molecules with SARS-CoV-2 peptides.

Keywords: COVID-19; HLA; MHC-I; diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest. All authors report no conflicts of interest.

Figures

Fig. 1.
Fig. 1.
(a) Maximum concentration of CRP in the comparison groups. (b) Maximum concentration of D-dimer in the comparison groups.
Fig. 2.
Fig. 2.
Correlation between the risk index for severe COVID-19 and the actual course of the disease in the comparison groups.
See this image and copyright information in PMC

References

    1. Shafiee A. Comparison of COVID-19 outcomes in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. Syndr.: Clin. Res. Rev. 2022;16:102512. doi: 10.1016/j.dsx.2022.102512. - DOI - PMC - PubMed
    1. Yang J.K., Feng Y., Yuan M.Y. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet. Med. 2006;23:623–628. doi: 10.1111/j.1464-5491.2006.01861.x. - DOI - PubMed
    1. Šestan M., Marinović S., Kavazović I. Virus-induced interferon-γ causes insulin resistance in skeletal muscle and derails glycemic control in obesity. Immunity. 2018;49:164–177. doi: 10.1016/j.immuni.2018.05.005. - DOI - PubMed
    1. Kusnadi, A., Ramirez-Suastegui, C., Fajardo, V., et al., Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells, Sci. Immunol., 2021, vol. 6, no. 55. - PMC - PubMed
    1. Wherry E.J., Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. Am. Soc. Microbiol. 2004;78:5535–5545. - PMC - PubMed

Substances